HeartSciences Announces Baker Institute ECG LV Dysfunction Study Results Published in JACC — Cardiovascular Imaging

Southlake, TX — HeartSciences, a medical device company focused on advancing the field of electrocardiology through innovation, announced the results of a study by Australia's Baker Heart and Diabetes Institute focused on identifying asymptomatic heart failure patients using machine learning based ECG testing.

The results were published in JACC — Cardiovascular Imaging. The article, by Elizabeth L. Potter, MBBS, BSc, Thomas H. Marwick, MBBS, PhD, MPH, Partho P. Sengupta, MD, et al., is titled "Machine Learning of ECG Waveforms to Improve Selection for Testing for Asymptomatic Left Ventricular Dysfunction." The machine learning ECG algorithm using MyoVista wavECG™ technology was developed to determine if it could effectively screen for LV dysfunction in asymptomatic patients with ejection fraction greater than 40%.

The study included 398 participants (57% female, median age 69 years), of whom 171 (43%) had LV dysfunction. The developed algorithm using continuous-wavelet-transform features alone was tested in an independent group (n=111; 49% female, median age 61 years), and demonstrated 88% sensitivity and 70% specificity, with an area under the curve (AUC) of 0.78, versus an AUC of 0.72 for the ARIC HF risk score and 0.53 for NT-proBNP.

"Conventional candidates for LVD screening (ARIC score, N-terminal pro-B-type natriuretic peptide, and standard automated ECG analysis) had inferior discriminative ability. Integration of ewECG [HeartSciences wavECG] in screening of people at risk of HF would reduce need for echocardiography by 45% while missing 12% of LVD cases," the study concluded.

"This new study by Baker Institute using MyoVista's wavECG technology further demonstrates the ability of MyoVista wavECG technology to detect LV dysfunction," said Mark Hilz, President and CEO of HeartSciences. "This study further indicates that HeartSciences' MyoVista technology has the capability and opportunity to bridge the diagnostic gap in heart disease," said Andrew Simpson, Chairman of HeartSciences.